# Bertha madras on X > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/bertha-madras-on-x/ > **Published:** 2026-09-04T17:23:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:45-04:00 > **Clinical Summary:** Explore the distinct binding mechanisms of THC and 2-AG on CB1 receptors, highlighting their implications for cannabis therapy and receptor health. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. THCNeurologyDosingSafetyResearchPolicyPain Why This Matters This article matters for clinicians and their patients as it discusses the differences between THC and 2-AG (a cannabinoid) in terms of CB1 receptor binding. Understanding these distinctions can help healthcare professionals better comprehend the pharmacological effects of cannabis, which is crucial for managing patient care, particularly in relation to potential side effects and therapeutic applications. This knowledge can aid in optimizing treatment plans and improving patient outcomes. Clinical Summary In this article, Bertha Madras discusses the differences between tetrahydrocannabinol (THC) and 2-arachidonoylglycerol (2-AG) in their binding to cannabinoid receptors, specifically the CB1 domain. This distinction leads to varying effects on the [endocannabinoid system](https://cedclinic.com/cbd-gummies-diabetes-management-evidence-safety/), which may have implications for clinicians when considering the therapeutic use of cannabis and its potential side effects for patients. The practical takeaway is that understanding these differences can aid in the informed prescribing and management of cannabis-based treatments. Dr. Caplan’s Take “As a seasoned family physician specializing in [cannabis medicine](https://cedclinic.com/cbd-gummies-smoking-cessation/), the recent findings on X offer intriguing insights into the distinct mechanisms of THC and 2-AG at CB1 receptors. While these results warrant further investigation in human subjects, they could potentially pave the way for more targeted therapies in our ongoing quest to optimize cannabis-based treatments.” – Dr. Benjamin Caplan, MD Clinical Perspective 🔬 In the article discussing Bertha Madras’ work on X, it’s highlighted that tetrahydrocannabinol (THC) and 2-arachidonoylglycerol (2-AG) interact differently with cannabinoid receptors, particularly CB1. This distinction is significant as it may influence the clinical effects of cannabis in patients. However, it’s important to acknowledge that the complexity of the endocannabinoid system and individual variability can confound these findings. In practice, healthcare providers should remain vigilant about potential cannabis-related side effects and adjust treatment plans accordingly, considering each patient’s unique response to cannabis and other medications. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Bertha%20madras%20on%20X%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D76505)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D76505)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Bertha%20madras%20on%20X%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D76505)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://x.com/madras_bertha/status/2095513715470667881](https://x.com/madras_bertha/status/2095513715470667881) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).